PARADIGM-2: Two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT status

Glioblastoma has a dismal prognosis and molecular targeted agents have failed to improve outcomes to date. PARADIGM-2 is a phase I dose escalation study evaluating olaparib plus radiotherapy ± temozolomide in newly diagnosed glioblastoma, using MGMT methylation status to stratify patients and inform...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Clin Transl Radiat Oncol
Prif Awduron: Fulton, Ben, Short, Susan C., James, Allan, Nowicki, Stefan, McBain, Catherine, Jefferies, Sarah, Kelly, Caroline, Stobo, Jon, Morris, Anna, Williamson, Aoife, Chalmers, Anthony J.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Elsevier 2017
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5862667/
https://ncbi.nlm.nih.gov/pubmed/29594237
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ctro.2017.11.003
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg